Cross Road Biotech Inversiones Biotecnológicas (CRB Inverbío SGEIC SA) is a leading Spanish Venture Capital Firm that invests in innovative early stage technology-based companies in the field of Life Sciences, Biotech, Med Tech and related fields.
The target investments propose innovative solutions to unmet medical needs in a cost-effective way and address global markets with high growth rates and volumes.
CRB Inverbío plays an active role in the development of the portfolio companies, supporting the teams and the strategic management all the way through the divestment process.
CRB Inverbío counts on the support of a strong top and core management team led by Enrique Castellón that provides value since the beginning
At present, CRB Inverbío manages two funds totaling more than €50M and has a portfolio of 14 companies.
CRB Inverbío and its funds are regulated by the National Securities Market Commission and remain committed to the highest standards of corporate governance and transparency.